tbuckley/cabot-search huggingface dataset:
Hereditary Cancer Syndromes—A Broader Clinical Spectrum Than Previously Understood?—Reply
Authors: Chenjie Zeng, Georgia L. Wiesner, Joshua C. Denny
Journal: JAMA Oncology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Global Frequency and Clinical Features of Stroke in Patients With Tuberculous Meningitis
Authors: Marie Charmaine C. Sy, Adrian I. Espiritu, Jose Leonard R. Pascual
Journal: JAMA Network Open (2022)

<h3>Importance</h3> Stroke in tuberculous meningitis (TBM) is associated with significant morbidity and mortality. <h3>Objective</h3> To determine the country-specific, regional, and overall prevalence of stroke among patients with TBM, including their clinical manifestations, stroke locations, and outcomes. <h3>Evidence Review</h3> This systematic review searched records in MEDLINE by PubMed, Scopus, and EMBASE until July 2020 for relevant articles on the occurrence and characteristics of stroke in TBM. Randomized clinical trials and cohort studies that included a population of patients with TBM were analyzed for clinical manifestations, type of stroke, area of stroke, vascular territory, and outcomes. Studies that did not report the occurrence of stroke, reported as abstract only with no full-texts available, and articles not in English were excluded. The country-specific, regional, and overall frequencies of stroke among patients with TBM were determined; secondary analysis enumerated the summary estimates of the clinical presentations, common locations of stroke, and outcomes. The Murad tool was used to assess methodological quality. <h3>Findings</h3> From 852 articles identified, 71 studies involving 2194 patients with stroke in TBM were included. The sample size for each study ranged from 17 to 806 patients. The frequency of stroke in TBM showed an estimate of 0.30 (95% CI, 0.26-0.33). The most common clinical manifestations were fever and headache. The lateral striate, middle cerebral, and medial striate arteries were typically affected. The basal ganglia, cortex and lobar, and internal capsule were the frequently involved areas of the brain. The pooled proportions of mortality and poor outcomes were 0.22 (95% CI, 0.16-0.29) and 0.51 (95% CI, 0.37-0.66), respectively. <h3>Conclusions and Relevance</h3> The results of this systematic review suggest that stroke is considerably frequent among patients with TBM. The reported frequencies of stroke in TBM and its clinical features vary across the studies and populations.
Association of Self-reported Primary Care Physician Tolerance for Uncertainty With Variations in Resource Use and Patient Experience
Authors: Arabella S. Begin, Michael K. Hidrue, Sara Lehrhoff, Inga T. Lennes, Katrina Armstrong, Jeffrey B. Weilburg, Marcela G. del Carmen, Jason H. Wasfy
Journal: JAMA Network Open (2022)

Inappropriate variations in clinical practice are a known cause of poor quality and safety, with variations often associated with nonclinical factors, such as individual differences in cognitive processing. The differential response of physicians to uncertainty may explain some of the variations in resource use and patient experience.
Disease burden, risk factors, and trends of primary central nervous system (CNS) cancer: A global study of registries data
Authors: Junjie Huang, Sze Chai Chan, Veeleah Lok, Lin Zhang, Xu Lin, Don Eliseo Lucero-Prisno, Wanghong Xu, Zhi-Jie Zheng, Edmar Elcarte, Mellissa Withers, Martin C S Wong
Journal: Neuro-Oncology (2022)

This study aimed to evaluate the global incidence, mortality, associated risk factors, and temporal trends of central nervous system (CNS) cancer by sex, age, and country.We extracted incidence and mortality of CNS cancer from the GLOBOCAN (2020), Cancer Incidence in Five Continents series I-X, WHO mortality database, the Nordic Cancer Registries, and the Surveillance, Epidemiology, and End Results Program. We searched the Global Health data exchanges for the prevalence of its associated risk factors. We tested the trends by Average Annual Percentage Change (AAPC) from Joinpoint regression analysis with 95% confidence intervals in different age groups.The age-standardized rates (ASRs) of CNS cancer incidence and mortality were 3.5 and 2.8 per 100,000 globally. Southern Europe (ASR = 6.0) and Western Asia (ASR = 4.2) had the highest incidence and mortality, respectively. The incidence was associated with Human Development Index, Gross Domestics Products per capita, prevalence of traumatic brain injuries, occupational carcinogens exposure, and mobile phone use at the country level. There was an overall stable and mixed trend in the CNS cancer burden. However, increasing incidence was observed in younger male population from five countries, with Slovakia (AAPC = 5.40; 95% CI 1.88, 9.04; P = .007) reporting the largest increase.While the overall global trends of cancer have been largely stable, significant increasing trends were found in the younger male population. The presence of some higher-HDI countries with increasing mortality suggested an ample scope for further research and exploration of the reasons behind these epidemiological trends.
The <i>American Journal of Psychiatry</i>’s Efforts Toward Eliminating Racism, Social Injustice, Health Care Inequities, and Publication Biases
Authors: Ned H. Kalin, Elisabeth B. Binder, Kathleen T. Brady, David A. Lewis, William M. McDonald, Daniel S. Pine, Carolyn I. Rodriguez, Michael D. Roy
Journal: American Journal of Psychiatry (2022)
Incidence Trends of Primary Cutaneous T-Cell Lymphoma in the US From 2000 to 2018
Authors: Zhuo Ran Cai, Michael L. Chen, Martin A. Weinstock, Youn H. Kim, Roberto A. Novoa, Eleni Linos
Journal: JAMA Oncology (2022)

Using SEER database data, this cohort study analyzed cutaneous T-cell lymphoma incidence by tumor subtype, sex, age, race and ethnicity, socioeconomic status, and geography.
Hereditary Cancer Syndromes—A Broader Clinical Spectrum Than Previously Understood?
Authors: Susrutha Puthanmadhom Narayanan, Yana G. Najjar
Journal: JAMA Oncology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
The genomic landscape of pediatric acute lymphoblastic leukemia
Authors: Samuel W. Brady, Kathryn G. Roberts, Zhaohui Gu, Lei Shi, Stanley Pounds, Deqing Pei, Cheng Cheng, Yunfeng Dai, Meenakshi Devidas, Chunxu Qu, Ashley N. Hill, Debbie Payne-Turner, Xiaotu Ma, Ilaria Iacobucci, Pradyuamna Baviskar, Lei Wei, Sasi Arunachalam, Kohei Hagiwara, Yanling Liu, Diane A. Flasch, Yu Liu, Matthew Parker, Xiaolong Chen, Abdelrahman H. Elsayed, Omkar Pathak, Yongjin Li, Yiping Fan, J. Robert Michael, Michael Rusch, Mark R. Wilkinson, Scott Foy, Dale J. Hedges, Scott Newman, Xin Zhou, Jian Wang, Colleen Reilly, Edgar Sioson, Stephen V. Rice, Victor Pastor Loyola, Gang Wu, Evadnie Rampersaud, Shalini C. Reshmi, Julie Gastier-Foster, Jaime M. Guidry Auvil, Patee Gesuwan, Malcolm A. Smith, Naomi Winick, Andrew J. Carroll, Nyla A. Heerema, Richard C. Harvey, Cheryl L. Willman, Eric Larsen, Elizabeth A. Raetz, Michael J. Borowitz, Brent L. Wood, William L. Carroll, Patrick A. Zweidler-McKay, Karen R. Rabin, Leonard A. Mattano, Kelly W. Maloney, Stuart S. Winter, Michael J. Burke, Wanda Salzer, Kimberly P. Dunsmore, Anne L. Angiolillo, Kristine R. Crews, James R. Downing, Sima Jeha, Ching-Hon Pui, William E. Evans, Jun J. Yang, Mary V. Relling, Daniela S. Gerhard, Mignon L. Loh, Stephen P. Hunger, Jinghui Zhang, Charles G. Mullighan
Journal: Nature Genetics (2022)
Glutaminase Inhibitors—Do They Have a Role in the Treatment of Metastatic Clear-Cell Renal Cell Carcinoma?
Authors: Janet E. Brown
Journal: JAMA Oncology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
IL1R2 increases regulatory T cell population in the tumor microenvironment by enhancing MHC-II expression on cancer-associated fibroblasts
Authors: Lujun Chen, Hao Huang, Xiao Zheng, Yuan Li, Junjun Chen, Bo Tan, Yingting Liu, Runzi Sun, Bin Xu, Min Yang, Bin Li, Changping Wu, Binfeng Lu, Jingting Jiang
Journal: Journal for ImmunoTherapy of Cancer (2022)

Background Regulatory T cells (Treg) are an integral part of the tumor immune tolerance. Carcinoma-associated fibroblasts (CAFs) is a pivotal driver for accumulation of Treg cells in the tumor microenvironment (TME). The molecular nature underpinning Treg cells and CAFs coupling needs to be further defined. Methods The Il1r2 flox/flox Foxp3 Cre mice were generated to establish the conditional knock-out of Il1r2 in Foxp3 + Tregs in vivo. Using the MC38 tumor model, we evaluated the antitumor efficacy of immune checkpoint inhibitors (ICIs) and further analyzed the immune profiling of the TME by multicolor flow cytometry. Single-cell RNA sequencing of the whole tumor tissues, TCR repertoire analysis of sorted CD3 + TILs were also performed. Results We showed that IL1 receptor 2 (IL1R2), a decoy receptor that neutralizes IL1, was highly expressed in Treg cells in the TME. In addition, we found that Il1r1 was largely expressed in the CAFs, suggesting IL1R2 plays a role in modulating crosstalk between Tregs and CAFs. We further demonstrated that Il1r2 deficiency in Treg cells led to greater antitumor efficacy of ICI, decreased Tregs and increased CD8 + T cells in the TME, as well as reduced levels of T cell dysfunction. Mechanistically, we showed that IL1 inhibited major histocompatibility complex class II (MHC-II) expression on fibroblasts and Treg-specific Il1r2 deletion led to a decrease in genes associated with MHC-II antigen presentation in CAFs. Conclusions Our study established a critical role of IL1 signaling in inhibiting Treg-mediated tumor immune suppression through downregulating MHC-II antigen presentation in CAFs.
The Intergenerational Transmission of Anxiety Disorders and Major Depression
Authors: Frances Rice
Journal: American Journal of Psychiatry (2022)

r e s sio n.Am e ric a n Jou r n al of P sy c hi a t ry 1 7 9 (9) , p p . 5 8 9-6 9 1. 1 0 . 1 1 7 6/ a p pi. aj p. 2
Genetic Ancestry Correlates with Somatic Differences in a Real-World Clinical Cancer Sequencing Cohort
Authors: Kanika Arora, Thinh N. Tran, Yelena Kemel, Miika Mehine, Ying L. Liu, Subhiksha Nandakumar, Shaleigh A. Smith, A. Rose Brannon, Irina Ostrovnaya, Konrad H. Stopsack, Pedram Razavi, Anton Safonov, Hira A. Rizvi, Matthew D. Hellmann, Joseph Vijai, Thomas C. Reynolds, James A. Fagin, Jian Carrot-Zhang, Kenneth Offit, David B. Solit, Marc Ladanyi, Nikolaus Schultz, Ahmet Zehir, Carol L. Brown, Zsofia K. Stadler, Debyani Chakravarty, Chaitanya Bandlamudi, Michael F. Berger
Journal: Cancer Discovery (2022)

Abstract Accurate ancestry inference is critical for identifying genetic contributors of cancer disparities among populations. Although methods to infer genetic ancestry have historically relied upon genome-wide markers, the adaptation to targeted clinical sequencing panels presents an opportunity to incorporate ancestry inference into routine diagnostic workflows. We show that global ancestral contributions and admixture of continental populations can be quantitatively inferred using markers captured by the MSK-IMPACT clinical panel. In a pan-cancer cohort of 45,157 patients, we observed differences by ancestry in the frequency of somatic alterations, recapitulating known associations and revealing novel associations. Despite the comparable overall prevalence of driver alterations by ancestry group, the proportion of patients with clinically actionable alterations was lower for African (30%) compared with European (33%) ancestry. Although this result is largely explained by population-specific cancer subtype differences, it reveals an inequity in the degree to which different populations are served by existing precision oncology interventions. Significance: We performed a comprehensive analysis of ancestral associations with somatic mutations in a real-world pan-cancer cohort, including &amp;gt;5,000 non-European individuals. Using an FDA-authorized tumor sequencing panel and an FDA-recognized oncology knowledge base, we detected differences in the prevalence of clinically actionable alterations, potentially contributing to health care disparities affecting underrepresented populations. This article is highlighted in the In This Issue feature, p. 2483
Errors in Abstract and Affiliations
Authors: Bishal Gyawali, Elizabeth Eisenhauer, Michael Brundage
Journal: JAMA Oncology (2022)

Charles Faselis, MD; Joel A. Nations, MD; Charity J. Morgan, PhD; Jared Antevil, MD; Jeffrey M. Roseman, MD, PhD, MPH; Sijian Zhang, MB, MS, MPH; Gregg C. Fonarow, MD; Helen M. Sheriff, MD; Gregory D. Trachiotis, MD; Richard M. Allman, MD; Prakash Deedwania, MD; Qing Zeng-Trietler, PhD; Daniel D. Taub, PhD; Amiya A. Ahmed, MD; George Howard, DrPH; Ali Ahmed, MD, MPH
Sex-Specific Factors Associated With Atrial Fibrillation in Women—Rhythm of Reproductive Health
Authors: Erin D. Michos, Michael C. Honigberg
Journal: JAMA Network Open (2022)

Zuolin Lu, MSc; Elif Aribas, MD, MSc; Sven Geurts, MD, MSc; Jeanine E. Roeters van Lennep, MD, PhD; M. Arfan Ikram, MD, PhD; Maxime M. Bos, PhD; Natasja M. S. de Groot, MD, PhD; Maryam Kavousi, MD, PhD
ERS technical standards for using type III devices (limited channel studies) in the diagnosis of sleep disordered breathing in adults and children
Authors: Renata L. Riha, Marta Celmina, Brendan Cooper, Refika Hamutcu-Ersu, Athanasios Kaditis, Andrew Morley, Athanasia Pataka, Thomas Penzel, Luca Roberti, Warren Ruehland, Dries Testelmans, Annelies van Eyck, Gert Grundström, Johan Verbraecken, Winfried Randerath
Journal: European Respiratory Journal (2022)

For more than three decades, type III devices have been used in the diagnosis of sleep disordered breathing in supervised as well as unsupervised settings. They have satisfactory positive and negative predictive values for detecting obstructive and central sleep apnoea in populations with moderately high pre-test probability of symptoms associated with these events. However, standardisation of commercially available type III devices has never been undertaken and the technical specifications can vary widely. None have been subjected to the same rigorous processes as most other diagnostic modalities in the medical field. Although type III devices do not include acquisition of electroencephalographic signals overnight, the minimum number of physical sensors required to allow for respiratory event scoring using standards outlined by the American Academy of Sleep Medicine remains debatable. This technical standard summarises data on type III studies published since 2007 from multiple perspectives in both adult and paediatric sleep practice. Most importantly, it aims to provide a framework for considering current type III device limitations in the diagnosis of sleep disordered breathing while raising research- and practice-related questions aimed at improving our use of these devices in the present and future.
Statin Therapy in Persons Receiving Dialysis—Does Peripheral Artery Disease Change the Equation?
Authors: Pranav S. Garimella, Sue Duval
Journal: JAMA Network Open (2022)

Hao-Yun Lo, MD; Yu-Sheng Lin, MD, PhD; Donna Shu-Han Lin, MD; Jen-Kuang Lee, MD, PhD; Wen-Jone Chen, MD, PhD
Assessment of Pretreatment and Posttreatment Evolution of Neurofilament Light Chain Levels in Patients Who Develop Immune Effector Cell–Associated Neurotoxicity Syndrome
Authors: Omar H. Butt, Alice Y. Zhou, Paolo F. Caimi, Patrick H. Luckett, Julie K. Wisch, Paul-Robert Derenoncourt, Kenneth Lee, Gregory F. Wu, Marcos J. G. de Lima, Jian L. Campian, Matthew J. Frank, John F. DiPersio, Armin Ghobadi, Beau M. Ances
Journal: JAMA Oncology (2022)

Determining whether neurofilament light chain (NfL) elevations in patients who develop immune effector cell-associated neurotoxicity syndrome (ICANS) occur before or after infusion of cellular product is important to identify high-risk patients and inform whether neuroaxonal injury is latent or a consequence of treatment.
Platelets control liver tumor growth through P2Y12-dependent CD40L release in NAFLD
Authors: Chi Ma, Qiong Fu, Laurence P. Diggs, John C. McVey, Justin McCallen, Simon Wabitsch, Benjamin Ruf, Zachary Brown, Bernd Heinrich, Qianfei Zhang, Umberto Rosato, Sophie Wang, Linda Cui, Jay A. Berzofsky, David E. Kleiner, Dale B. Bosco, Long-Jun Wu, Chunwei Walter Lai, Yaron Rotman, Changqing Xie, Firouzeh Korangy, Tim F. Greten
Journal: Cancer Cell (2022)
Implementing Modernized Eligibility Criteria in US National Cancer Institute Clinical Trials
Authors: Andrea M Denicoff, S Percy Ivy, Tami T Tamashiro, Jinxiu Zhao, Katherine H Worthington, Margaret M Mooney, Richard F Little
Journal: JNCI Journal of the National Cancer Institute (2022)

In 2018, the Cancer Therapy Evaluation Program (CTEP) at the US National Cancer Institute published new protocol template language that focused on organ function and prior and concurrent cancers in an effort to modernize eligibility criteria for cancer treatment trials. We conducted an analysis of CTEP-supported trials to evaluate the uptake and incorporation of the new language. The analysis included evaluation of 122 protocols approved in the years 2018-2020 for inclusion of the modernized eligibility criteria and consistency with new protocol template language related to 7 major eligibility criteria. These were cardiac function, liver function, kidney function, HIV status, prior and/or concurrent malignancies, treated and/or stable brain metastasis, and new and/or progressive brain metastases. Overall, CTEP trials evaluated in this period demonstrated that eligibility criteria were implemented to a relatively high degree ranging from a low of 54.1% for prior and/or concurrent malignancies to a high of 93.4% for eligibility criteria related to HIV infection. The findings demonstrate that modernized eligibility criteria can be successfully implemented but that consistent implementation requires sustained focused effort. As a result of these findings, CTEP began a new initiative in January 2022 that incorporates a specific review of eligibility criteria for new protocols to promote and improve consistency with the modernization effort.
Blame and shame are harming our response to monkeypox
Authors: Duncan Shrewsbury
Journal: BMJ (2022)

monkeypoxOld stigmas are hampering how we understand, talk about, and respond to monkeypox, writes Duncan Shrewsbury Duncan Shrewsbury senior lecturer in general practiceNo sooner are we told to get used to living with the new normal of endemic variants of covid-19 than we are faced with another peril.The spread of monkeypox to the UK and other previously non-endemic countries has caused alarm.Just as worrying as the emergence of the virus in unexpected regions, however, is how it has reawakened harmful narratives about infectious diseases that I had hoped we'd left in the past.
Building on the journal’s success through collaboration and partnership
Authors: Susan M Chang
Journal: Neuro-Oncology (2022)

Journal Article Building on the journal’s success through collaboration and partnership Get access Susan M Chang Susan M Chang Department of Neurological Surgery, University of California at San Francisco, San Francisco, CA, USA Corresponding Author: Susan M. Chang, MD, Department of Neurological Surgery, University of California at San Francisco, 400 Parnassus Ave., A 808, Box 0372, San Francisco, CA 94143-0372, USA (Susan.Chang@ucsf.edu). Search for other works by this author on: Oxford Academic PubMed Google Scholar Neuro-Oncology, Volume 24, Issue 9, September 2022, Page 1407, https://doi.org/10.1093/neuonc/noac184 Published: 01 September 2022 Article history Corrected and typeset: 01 September 2022 Published: 01 September 2022
Consensus on the clinical management of chronic radiation dermatitis and radiation fibrosis: a Delphi survey
Authors: Britney N. Wilson, Rohan Shah, Christian Menzer, Abdullah Aleisa, Mary D. Sun, Bernice Y. Kwong, Ben H. Kaffenberger, Lucia Seminario-Vidal, Christopher A. Barker, Michael D. Stubblefield, Paul B. Romesser, Gabriella Fabbrocini, Murad Alam, Farah Abdulla, Brittany Dulmage, Vincent Sibaud, Milan Anadkat, Jean-Michel Mazer, Dhwani Parikh, Beth McLellan, Hugues Cartier, Silvina Pugliese, Albert Wolkerstorfer, Hans-Joachim Laubach, Nicole LeBoeuf, Jonathan Leventhal, Derrick C. Wan, Jennifer Choi, Thanh Nga Tran, R. Rox Anderson, Alina Markova, Anthony Rossi
Journal: British Journal of Dermatology (2022)